Xcout Intel
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. is a U.S.-based biotechnology company specializing in the discovery and development of RNA-targeted therapeutic agents. The company's commercialized portfolio features SPINRAZA, a treatment for spinal muscular atrophy (SMA) in both pediatric and adult patients. It also offers TEGSEDI, an injectable therapy for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, and WAYLIVRA, approved for familial chylomicronemia syndrome and familial partial lipodystrophy. Beyond its marketed therapies, Ionis is actively progressing numerous drug candidates through pivotal Phase 3 clinical trials. These late-stage programs include Eplontersen, a monthly self-administered subcutaneous injection targeting all types of TTR amyloidosis; Olezarsen, designed for patients with severe hypertriglyceridemia (SHTG); Donidalorsen, for hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis; Pelacarsen, for individuals with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, developed to inhibit superoxide dismutase 1 production. Furthermore, Ionis is exploring treatments across a broader spectrum of therapeutic areas, such as metabolic, infectious, renal, ophthalmic diseases, and cancer. The company maintains a significant strategic collaboration with Biogen Inc. and holds various collaboration and licensing agreements with other prominent pharmaceutical partners, including AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Founded in 1989, Ionis Pharmaceuticals, Inc. operates from its headquarters in Carlsbad, California.
Subscribe to see Ionis Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Ionis Pharmaceuticals, Inc. at a glance
Ionis Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in Carlsbad, United States. It is publicly listed (0JDI) with a market capitalisation of $9.2B. Xcout tracks 60 named people at Ionis Pharmaceuticals, Inc., including Brett P. Monia, Ph.D. (Chief Executive Officer).
Ionis Pharmaceuticals, Inc. leadership
- Brett P. Monia, Ph.D.Chief Executive Officer
- Elizabeth L. HougenExecutive Vice President of Finance & Chief Financial Officer
- Patrick R. O'NeilExecutive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary
- C. Frank BennettExecutive Vice President & Chief Scientific Officer
- C. Frank Bennett, Ph.D.Executive Vice President, Chief Scientific Officer
- Darren GonzalesChief Accounting Officer & Senior Vice President
54 more named people on record for Ionis Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Get Ionis Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Ionis Pharmaceuticals, Inc. in Xcout Intel
- 60 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access